Pharmaron Beijing Co (HKSE:03759) Other Financing: HK$1,097 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:03759 Pharmaron Beijing Co Ltd HKSE:03759
90 GF Score
Price HK$33.20
GF Value HK$23.31
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Pharmaron Beijing Co Other Financing?

Pharmaron Beijing Co HKSE:03759 -1.95% 90 Other Financing is HK$1,097 Mil as of Jun. 2026. GuruFocus rates HKSE:03759 with a GF Score™ of 90/100 and a GF Value™ of HK$23.31 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Pharmaron Beijing Co's Other Financing for the three months ended in Jun. 2026 was HK$-109 Mil.

Pharmaron Beijing Co's Other Financing for the trailing twelve months (TTM) ended in Jun. 2026 was HK$1,097 Mil.

Pharmaron Beijing Co Other Financing Historical Data

* Premium members only.

The historical data trend for Pharmaron Beijing Co's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmaron Beijing Co Other Financing Chart

Pharmaron Beijing Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -632.75 -1,105.25 818.49 -515.74 -207.17

Pharmaron Beijing Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -46.70 -75.35 -9.29 1,290.21 -108.55
HKSE:03759
90GF Score
Pharmaron Beijing Co Ltd HKSE:03759
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharmaron Beijing Co Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$1,097 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of HK$1,097 Mil mean?
Pharmaron Beijing Co (HKSE:03759) has a Other Financing of HK$1,097 Mil as of Jun. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Pharmaron Beijing Co and its competitors.
Is Pharmaron Beijing Co's Other Financing too high?
Pharmaron Beijing Co's current Other Financing is HK$1,097 Mil. Overall, Pharmaron Beijing Co has a GF Score™ of 90/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pharmaron Beijing Co's Other Financing compare to VRTX and REGN?
Pharmaron Beijing Co's Other Financing of HK$1,097 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Pharmaron Beijing Co and its competitors. Pharmaron Beijing Co's current Other Financing is HK$1,097 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmaron Beijing Co stock overvalued right now?
Based on GuruFocus' analysis, Pharmaron Beijing Co (HKSE:03759) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$23.31, compared to a current price of HK$33.20 — trading 42.4% above its estimated fair value. The current Other Financing is HK$1,097 Mil. Pharmaron Beijing Co's overall GF Score™ is 90/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Pharmaron Beijing Co (HKSE:03759), the current Other Financing is HK$1,097 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharmaron Beijing Co (HKSE:03759) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmaron Beijing Co stock appears to be overvalued. The current stock price of HK$33.20 is trading 42.4% above its estimated GF Value™ of HK$23.31. GuruFocus considers Pharmaron Beijing Co to be Significantly Overvalued.

Key valuation signals for HKSE:03759:

  • Other Financing: HK$1,097 Mil
  • GF Value™: HK$23.31 vs. price of HK$33.20 (42.4% above fair value)
  • GF Score™: 90/100 with 8 warning signs

No single metric tells the full story. See the HKSE:03759 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharmaron Beijing Co Business Description

Other Exchanges 17Q1:Germany300759:China
Address 6 Tai-He Road, 8th Floor, Block 1, Beijing Economic Technological Development Area, Beijing, CHN, 100176
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal, and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry, and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. Its operating segment includes Laboratory services; CMC (small molecule CDMO) services, Clinical development services, and biologics and CGT services. It generates maximum revenue from the Laboratory services segment.
90GF Score

Get the complete analysis for HKSE:03759

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$33.20
Price
HK$23.31
GF Value